LG Chem 
Welcome,         Profile    Billing    Logout  
 40 Products   109 Diseases   40 Products   37 Trials   1902 News 


«12...7891011121314151617...1920»
  • ||||||||||  Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy:  INTESTINE: Initial Combination of Gemigliptin and Metformin on Microbiota Change (clinicaltrials.gov) -  Apr 8, 2020   
    P=N/A,  N=70, Active, not recruiting, 
    ClinicalTrials.gov Identifier: NCT03355014. Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  ficlatuzumab (AV-299) / LG Chem
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Combination therapy:  CyFi2: A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Mar 31, 2020   
    P2,  N=0, Withdrawn, 
    This raises the general concept that proteins involved in cytoskeletal functions and appearing organism-specific, may have highly divergent and cryptic orthologs in other species. N=60 --> 0 | Trial completion date: Mar 2022 --> Mar 2020 | Not yet recruiting --> Withdrawn | Trial primary completion date: Feb 2021 --> Mar 2020
  • ||||||||||  ficlatuzumab (AV-299) / LG Chem
    Trial completion date, Trial termination:  Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML (clinicaltrials.gov) -  Mar 24, 2020   
    P1,  N=17, Terminated, 
    N=60 --> 0 | Trial completion date: Mar 2022 --> Mar 2020 | Not yet recruiting --> Withdrawn | Trial primary completion date: Feb 2021 --> Mar 2020 Trial completion date: Jun 2020 --> Dec 2019 | Active, not recruiting --> Terminated; Low Accrual
  • ||||||||||  Fotivda (tivozanib) / EUSA Pharma, AVEO
    Sitagliptin does not stabilize a VEGF-A-challenged barrier of retinal endothelial cells (Exhibit Hall: Posterboard# B0187) -  Mar 9, 2020 - Abstract #ARVO2020ARVO_2180;    
    CD9 was localized at the plasma membrane in untreated or tivozanib-rescued VEGFA-challenged iBREC but it was concentrated at the foci of iBREC exposed to VEGFA or VEGFA plus sitagliptin.Conclusions Sitagliptin neither enhanced nor reverted the detrimental action of VEGFA on the stability of the iBREC barrier despite increasing the amount of the TJ-protein claudin-1. The low CI rather correlated with a low expression and a changed subcellular localization of the tetraspanin CD9 confirming the hypothesis that sitagliptin might interfere with interaction of REC with the extracellular matrix.
  • ||||||||||  tacrolimus / Generic mfg., sirolimus / Generic mfg., Gemiglo (gemigliptin) / Sanofi, LG Chem
    Clinical, Journal:  Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus. (Pubmed Central) -  Mar 8, 2020   
    The low CI rather correlated with a low expression and a changed subcellular localization of the tetraspanin CD9 confirming the hypothesis that sitagliptin might interfere with interaction of REC with the extracellular matrix. Gemigliptin robustly lowered blood glucose levels without exerting any significant effect on immunosuppressive treatment, renal function, and liver enzymes in post-transplant patients with T2D.
  • ||||||||||  Fotivda (tivozanib) / EUSA Pharma, AVEO
    Clinical, Review, Journal:  Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. (Pubmed Central) -  Feb 23, 2020   
    Among them, tivozanib is one of the last TKIs introduced in the clinical practice; this drug selectively targets VEGFRs, it is characterized by a favorable pharmacokinetics and safety profile and has been approved as first-line treatment for patients with metastatic RCC (mRCC). In this article, we describe the clinical pharmacology of selected VEGFR-TKIs used for the treatment of mRCC, highlighting the relevant differences; moreover we aim to define the main pharmacologic characteristics of these drug.
  • ||||||||||  MP412 / Mitsubishi Tanabe
    Meet the Professor Seminar. MP412. DIAGNOSTICS AND THERAPEUTIC INTERVENTIONS IN LATENT, INCIPIENT, AND SUBCLINICAL TB INFECTIONS (PHILADELPHIA MARRIOTT DOWNTOWN, Room 407 (Level 4)) -  Jan 30, 2020 - Abstract #ATS2020ATS_1827;    
    Participants will be able to learn new diagnostic and therapeutic strategies, including promising technologies to optimally manage patients at risk of TB infection in the U.S. and TB endemic areas. Participants will learn new findings and translational data and trials to be better prepared for future implementation of optimal preventive and strategies to improve TB control in the U.S. and TB endemic areas
  • ||||||||||  tigulixostat (LC350189) / LG Chem
    Trial completion date:  A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia (clinicaltrials.gov) -  Jan 22, 2020   
    P2,  N=190, Recruiting, 
    This review focuses on the existing evidence on patient-reported outcomes and health-related quality of life with several tyrosine kinase inhibitors (pazopanib, sunitinib, cabozantinib and tivozanib) used as first-line treatment for metastatic renal cell carcinoma. Trial completion date: Oct 2020 --> May 2021
  • ||||||||||  Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem, Sandoz
    Enrollment closed, Trial primary completion date:  GLITTER 1: Gan & Lee Insulin Glargine Target Type (1) Evaluating Research (clinicaltrials.gov) -  Jan 21, 2020   
    P3,  N=550, Active, not recruiting, 
    Trial completion date: Oct 2020 --> May 2021 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2019 --> Feb 2020
  • ||||||||||  Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem, Sandoz
    Enrollment closed, Trial primary completion date:  GLITTER 2: Gan & Lee Insulin Glargine Target Type (2) Evaluating Research (clinicaltrials.gov) -  Jan 18, 2020   
    P3,  N=550, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2019 --> Feb 2020 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2019 --> Feb 2020
  • ||||||||||  Follitrope (recombinant human follicle stimulating hormone) / LG Chem
    New trial:  Observational Study to Develop Dosing Chart (clinicaltrials.gov) -  Jan 13, 2020   
    P,  N=1000, Recruiting,